Akari Therapeutics (AKTX) Competitors $1.38 -0.06 (-3.82%) As of 09:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. TLSA, NKTX, LYEL, SCPH, LRMR, CTNM, KRRO, OGI, EPRX, and CGENShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Tiziana Life Sciences (TLSA), Nkarta (NKTX), Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), Korro Bio (KRRO), Organigram (OGI), Eupraxia Pharmaceuticals (EPRX), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Tiziana Life Sciences Nkarta Lyell Immunopharma scPharmaceuticals Larimar Therapeutics Contineum Therapeutics Korro Bio Organigram Eupraxia Pharmaceuticals Compugen Tiziana Life Sciences (NASDAQ:TLSA) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation. Does the media favor TLSA or AKTX? In the previous week, Tiziana Life Sciences and Tiziana Life Sciences both had 2 articles in the media. Akari Therapeutics' average media sentiment score of 0.94 beat Tiziana Life Sciences' score of 0.11 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Tiziana Life Sciences Neutral Akari Therapeutics Positive Which has higher earnings & valuation, TLSA or AKTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$17.69MN/AN/AAkari TherapeuticsN/AN/A-$10.01MN/AN/A Is TLSA or AKTX more profitable? Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Akari Therapeutics N/A N/A N/A Do institutionals & insiders believe in TLSA or AKTX? 5.1% of Akari Therapeutics shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 38.9% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, TLSA or AKTX? Tiziana Life Sciences has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Does the MarketBeat Community prefer TLSA or AKTX? Akari Therapeutics received 166 more outperform votes than Tiziana Life Sciences when rated by MarketBeat users. However, 63.58% of users gave Tiziana Life Sciences an outperform vote while only 49.81% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformTiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Akari TherapeuticsOutperform Votes26249.81% Underperform Votes26450.19% SummaryAkari Therapeutics beats Tiziana Life Sciences on 5 of the 7 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.29M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.4818.48Price / SalesN/A242.70395.93103.60Price / CashN/A65.8538.1834.62Price / Book-48.006.516.774.25Net Income-$10.01M$143.21M$3.22B$248.23M7 Day Performance-1.37%1.98%1.47%0.89%1 Month Performance30.91%6.89%3.99%3.53%1 Year Performance-15.29%-2.52%16.15%5.08% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari TherapeuticsN/A$1.39-3.8%N/A-6.5%$36.83MN/A0.009News CoverageGap UpTLSATiziana Life Sciences0.4731 of 5 stars$1.13+5.6%N/A+110.0%$132.04MN/A0.008Short Interest ↑News CoverageNKTXNkarta2.828 of 5 stars$1.85+2.2%$14.86+703.1%-68.3%$131.27MN/A-0.98140Upcoming EarningsPositive NewsLYELLyell Immunopharma3.4188 of 5 stars$0.44+0.9%$1.00+128.5%-78.1%$129.25M$61,000.00-0.55270Upcoming EarningsNews CoveragePositive NewsGap UpSCPHscPharmaceuticals3.7171 of 5 stars$2.56-0.4%$14.00+446.9%-43.0%$128.73M$36.33M-1.3530News CoveragePositive NewsLRMRLarimar Therapeutics1.741 of 5 stars$2.01+5.2%$19.63+876.4%-61.5%$128.70MN/A-1.7530Upcoming EarningsOptions VolumeNews CoveragePositive NewsCTNMContineum Therapeutics1.9983 of 5 stars$4.95+7.1%$24.80+401.0%-73.7%$128.07M$50M-1.0131News CoverageKRROKorro Bio1.4882 of 5 stars$13.64-1.9%$120.43+782.9%-68.7%$128.07M$2.27M-1.4570Analyst ForecastAnalyst RevisionNews CoveragePositive NewsOGIOrganigram0.8342 of 5 stars$1.00-6.5%N/A-45.3%$126.26M$166.12M-2.63860EPRXEupraxia Pharmaceuticals2.9698 of 5 stars$3.48+5.8%$10.50+201.7%+49.6%$124.76MN/A-4.8329Positive NewsGap UpHigh Trading VolumeCGENCompugen2.0649 of 5 stars$1.39-5.4%$4.00+187.8%-17.1%$124.04M$27.86M69.5070Positive News Related Companies and Tools Related Companies Tiziana Life Sciences Competitors Nkarta Competitors Lyell Immunopharma Competitors scPharmaceuticals Competitors Larimar Therapeutics Competitors Contineum Therapeutics Competitors Korro Bio Competitors Organigram Competitors Eupraxia Pharmaceuticals Competitors Compugen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKTX Stock Free AKTX Stock Alerts